CEO: Martin Rosendale
Ticker: OTC.BB: CMXI.OB
Aldagen was acquired by Cytomedix in February 2012. Cytomedix is developing Aldagen's regenerative cell therapies that target significant unmet medical needs. The company is developing and commercializing proprietary products that identify unique populations of adult stem cells that have the potential to revolutionize treatments of cancer, cardiovascular disease and other degenerative diseases.